हिंदी में पढ़ें —JantaScope हिंदी
Viral

Supreme Court Questions 10-Fold Gap in Cancer Drug Pricing, Flags ₹2,700-to-₹27,000 MRP Disparity

The Supreme Court has raised serious concerns over large gaps between the price at which some medicines reach retailers and the maximum retail price printed for patients. During a hearing on drug-price regulation, the Court cited an essential cancer medicine carrying an MRP of ₹27,000 despite a price-to-retailer of ₹2,700, and questioned whether India's existing framework adequately protects patients from excessive margins.

Supreme Court Questions 10-Fold Gap in Cancer Drug Pricing, Flags ₹2,700-to-₹27,000 MRP Disparity

By Jeet Nirmal

Source: Business Standard

Supreme Court Questions 10x Gap in Cancer-Drug Pricing, Seeks Answers on Price Controls

NEW DELHI, September 23, 2026: The Supreme Court has questioned what it described as an alarming disparity in medicine pricing after being told that an essential cancer drug with a Price to Retailer (PTR) of ₹2,700 carried a Maximum Retail Price (MRP) of ₹27,000 — ten times the retailer price.

A Bench of Justices Vikram Nath and Sandeep Mehta raised the issue on Tuesday while hearing petitions concerning medicine-price regulation, generic prescribing, medical devices and the pricing of drugs that fall outside scheduled price controls.

Justice Mehta described the example before the Court as “broad daylight dacoity with the patients”, questioning how such a large gap could exist for an essential cancer medicine.

The Court's remarks put a spotlight on a broader issue: not simply what a medicine costs at the pharmacy counter, but how its printed MRP is determined and how much room India's regulatory framework leaves for margins across the pharmaceutical supply chain.

₹2,700 PTR, ₹27,000 MRP: What the Court Questioned

The cancer-drug example cited before the Bench showed a particularly striking difference:

Price to Retailer: ₹2,700
Maximum Retail Price: ₹27,000
Difference: ₹24,300
MRP/PTR ratio: 10 times

PTR and MRP are not expected to be identical. PTR generally refers to the price at which a medicine is supplied to a retailer or pharmacy, while the MRP represents the maximum amount that can be charged to the consumer. Distribution and retail margins can therefore create a difference between the two.

The Supreme Court's concern was about the scale of that difference in examples presented during the proceedings. Other examples reportedly placed before the Court included a medicine with an MRP of ₹73 and PTR of ₹22.75, and another carrying an MRP of ₹61 against a PTR of ₹9.65.

Court Highlights Financial Pressure on Cancer Patients

The Bench connected medicine pricing with the severe financial burden that serious illnesses can impose on families.

Justice Mehta remarked:

“People sell their houses, people sell their ornaments for getting the medicines.”

The Court questioned why authorities responsible for addressing the issue had not acted against disparities of the magnitude cited during the hearing.

The observations are particularly significant for cancer treatment, where patients may require multiple medicines and repeated treatment cycles, making even individual drug-price differences financially consequential.

Ayushman Bharat and the Cost to Taxpayers

The Court also examined the implications for publicly financed healthcare.

It observed that when treatment is provided under government health programmes such as Ayushman Bharat, hospitals can purchase medicines and subsequently seek reimbursement. In such circumstances, excessive prices would not affect only individual patients; public funds could ultimately bear the cost as well.

This expands the pricing question beyond affordability for individual patients to the efficiency of government healthcare expenditure.

Scheduled vs Non-Scheduled Medicines: Why It Matters

A major issue in the case concerns India's Drugs (Prices Control) Order, 2013 (DPCO).

Under the current framework, the National Pharmaceutical Pricing Authority (NPPA) fixes ceiling prices for medicines covered by Schedule I of the DPCO, which is linked to the National List of Essential Medicines.

The petitioners, however, focused attention on non-scheduled medicines.

Petitioner Kishan Chand Jain argued before the Court that while subsequent price increases for non-scheduled drugs are restricted, their initial launch prices are not subjected to the same kind of ceiling-price mechanism. He contended that this creates room for high initial MRPs and substantial trade margins.

These are submissions by the petitioner, rather than findings finally determined by the Supreme Court.

Government Says 131 Anti-Cancer Drugs Have Effective Ceiling Prices

Government data provides important context to the debate.

In a March 13, 2026 response, the government said that 131 anti-cancer drugs had effective ceiling prices as of March 9, 2026.

According to the government, these controls had produced an approximately 21% reduction in ceiling prices compared with those fixed under the National List of Essential Medicines 2015 framework, generating estimated annual patient savings of about ₹294 crore.

The government also stated that the NPPA had fixed 58 retail prices in the anti-cancer therapeutic category, covering 31 anti-cancer drugs, 26 anti-neoplastic drugs and one immunosuppressive drug as of March 9.

For non-scheduled anti-cancer formulations, manufacturers cannot increase the MRP by more than 10% of the formulation's MRP during the preceding 12 months, according to the government's description of the existing rules.

That distinction is central to the dispute before the Court: controls on later price increases do not necessarily answer the petitioners' concerns about how the initial price of a non-scheduled medicine is determined.

Pharma Industry Points to Retail and Hospital Margins

The hearing also brought out another side of the pricing debate.

Senior Advocate Kapil Sibal, representing the Indian Pharmaceutical Alliance, argued that pharmaceutical manufacturers themselves were not retaining the large margins being discussed and that the issue needed to be examined at the stockist, retailer and hospital levels.

Sibal told the Court that the price at which medicines are sold to stockists was an important part of understanding where the margins arise.

Justice Mehta, however, pointed to the manufacturer's role in fixing the MRP, highlighting why the Court wanted the entire pricing chain examined.

The exchange is important because a large PTR-to-MRP difference does not by itself establish which participant in the supply chain ultimately receives the entire difference.

Centre Says It Is Open to Improvements

Additional Solicitor General K M Nataraj, appearing for the Union government, told the Court that the Centre was not approaching the proceedings as an adversarial dispute and was willing to consider areas where the system could be improved.

He also referred to the Pradhan Mantri Bhartiya Janaushadhi Pariyojana, which provides lower-cost medicines through Janaushadhi Kendras.

The Court questioned what options remain for patients when the medicine they need is unavailable through those outlets.

Generic Medicines and Medical Devices Also Under Scrutiny

The proceedings extend beyond the specific cancer-drug example.

The petitions raise broader questions involving generic prescriptions, price regulation for non-scheduled medicines, medical-device MRPs and excessive trade margins.

One submission also raised concerns about the quality and reliability of generic medicines and argued that patients should retain a choice between generic and branded products.

The Court has not delivered a final ruling on these broader questions.

What Happens Next?

The Supreme Court has scheduled the matter for further hearing on September 29, 2026, when submissions from the Indian Pharmaceutical Alliance and the Union government are expected to continue.

For now, the ₹2,700-versus-₹27,000 example has brought renewed attention to a fundamental policy question: how should India balance pharmaceutical pricing, distribution margins and commercial considerations while ensuring that essential medicines remain affordable for patients?

The Court's observations are part of ongoing proceedings and should not be treated as a final judicial finding that every cancer drug, or the pharmaceutical industry generally, carries a ten-fold markup.

Related

More stories

Trump Suggests Iran Link in Flydubai Cockpit Attack as Investigation Continues

US President Donald Trump has suggested that the co-pilot accused of attacking Indian captain Smit Machchhar aboard a flydubai flight may have links to Iran. However, Trump said authorities were still investigating, while UAE officials have cautioned against drawing conclusions before evidence is established.

Viral

Trump Suggests Iran Link in Flydubai Cockpit Attack as Investigation Continues

‘There’s an Extra Pilot’: New Videos Capture Chaos Aboard Flydubai Flight After Cockpit Attack

Newly released footage from flydubai Flight FZ1073 shows passengers and crew responding to a violent cockpit incident that left Indian captain Smit Machchhar injured and forced the Dubai-to-Tel Aviv flight to divert to Tabuk, Saudi Arabia. The videos add new details about the tense moments aboard the aircraft, while authorities continue investigating what caused the confrontation.

Viral

‘There’s an Extra Pilot’: New Videos Capture Chaos Aboard Flydubai Flight After Cockpit Attack

Gandhi Jayanti 2026: Rajagopalachari’s 1968 Essay Revisited, Linking Gandhi’s Non-Violence to Faith

On Gandhi Jayanti 2026, Hindustan Times has republished edited excerpts from a 1968 article by C. Rajagopalachari examining the spiritual foundations of Mahatma Gandhi’s philosophy. Rajagopalachari argued that Gandhi’s commitment to truth, love and non-violence could not be understood merely as a political strategy, but was closely connected to his faith and moral convictions.

Viral

Gandhi Jayanti 2026: Rajagopalachari’s 1968 Essay Revisited, Linking Gandhi’s Non-Violence to Faith

Smit Machchhar’s Aviation Journey Draws Attention After Flydubai Mid-Air Emergency

Indian pilot Smit Machchhar’s journey into aviation has gained renewed attention after he was injured during a serious cockpit incident aboard a flydubai flight. An older interview in which he spoke about his mother’s initial concerns over his decision to become a pilot is now being widely discussed online.

Viral

Smit Machchhar’s Aviation Journey Draws Attention After Flydubai Mid-Air Emergency

‘Salary Below ₹1 Lakh? Think Twice Before Moving to Bengaluru,’ Employee’s Advice Sparks Debate

A Bengaluru-based professional’s warning about the city’s cost of living has triggered an online discussion, with social media users offering differing views on whether living in India’s technology hub really requires a high monthly salary.

Viral

‘Salary Below ₹1 Lakh? Think Twice Before Moving to Bengaluru,’ Employee’s Advice Sparks Debate

Gen Z Founder Says He Pays Double for Working on Days Off, Shares His Unusual Workplace Approach

A 25-year-old entrepreneur from Chandigarh has drawn attention online after sharing several unconventional practices he says shape the culture at his company. Among them: paying employees twice their normal rate when they give up a day off to work, spending heavily on team celebrations and allowing employees to openly roast him.

Viral

Gen Z Founder Says He Pays Double for Working on Days Off, Shares His Unusual Workplace Approach